Literature DB >> 29707312

Establishment of animal model of gastroesophageal reflux disease by per-oral endoscopic tunneling: a preliminary study.

Hai-Qing Hu1,2, Hui-Kai Li1, Ying Xiong1, Xiao-Bin Zhang1, Jun-Li Zhi1, Xiao-Xiao Wang1, En-Qiang Linghu1.   

Abstract

BACKGROUND: Although a variety of antireflux procedures and medications are used to treat gastroesophageal reflux disease (GERD), reliable large-animal models of GERD that can be used to objectively compare the efficacy of these treatments are lacking. We developed a method to establish large animal models of GERD by endoscopic sphincterotomy to develop an endoscopic treatment for GERD.
METHODS: In this study six flesh swine carcasses were used. A full thickness incision was made at the esophageal site 5 cm above the dentate line by per-oral endoscopic tunneling. Esophageal radiography was conducted before and after surgery to observe changes at the site of the lower esophagus 5 cm above the dentate line and in the cardia.
RESULTS: There was no significant change in the diameter of the esophageal site 5 cm above the dentate line before and after surgery, while the cardiac orifice significantly relaxed after surgery and enabled the contrast agent to smoothly travel through. The difference in diameter was statistically significant (P<0.05).
CONCLUSIONS: Our experiments showed that it is a minimally invasive and mature technology of establishing GERD animal models by using the per-oral endoscopic tunneling technique, and might be a new method to establishing GERD large animal models.

Entities:  

Keywords:  Gastroesophageal reflux disease (GERD); animal model; swine

Year:  2018        PMID: 29707312      PMCID: PMC5906314          DOI: 10.21037/jtd.2018.02.29

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  19 in total

Review 1.  The epidemiology of gastroesophageal reflux disease: what we know and what we need to know.

Authors:  G Eisen
Journal:  Am J Gastroenterol       Date:  2001-08       Impact factor: 10.864

2.  Ambulatory long-term pH monitoring in pigs.

Authors:  K A Gawad; R Wachowiak; C Rempf; W J Tiefenbacher; T Strate; E G Achilles; C Blöchle; J R Izbicki
Journal:  Surg Endosc       Date:  2003-08-15       Impact factor: 4.584

Review 3.  Endoscopic antireflux procedures.

Authors:  J Arts; J Tack; J P Galmiche
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

4.  Peroral endoscopic myotomy (POEM) for esophageal achalasia.

Authors:  H Inoue; H Minami; Y Kobayashi; Y Sato; M Kaga; M Suzuki; H Satodate; N Odaka; H Itoh; S Kudo
Journal:  Endoscopy       Date:  2010-03-30       Impact factor: 10.093

5.  Proton pump inhibitors in the management of GERD.

Authors:  Philip O Katz; Stacey Zavala
Journal:  J Gastrointest Surg       Date:  2009-09-23       Impact factor: 3.452

6.  Risk factors for Barrett's esophagus: a case-control study.

Authors:  Massimo Conio; Rosangela Filiberti; Sabrina Blanchi; Roberto Ferraris; Santino Marchi; Paolo Ravelli; Gabriella Lapertosa; Gaetano Iaquinto; Renato Sablich; Riccardo Gusmaroli; Hugo Aste; Attilio Giacosa
Journal:  Int J Cancer       Date:  2002-01-10       Impact factor: 7.396

7.  A canine model of gastroesophageal reflux disease (GERD).

Authors:  R L McMahon; A Ali; E G Chekan; E M Clary; M J Garcia-Oria; M C Fina; R L McRae; A Ko; A Gandsas; T N Pappas; W S Eubanks
Journal:  Surg Endosc       Date:  2001-10-19       Impact factor: 4.584

Review 8.  Effectiveness of proton pump inhibitors in nonerosive reflux disease.

Authors:  Bonnie B Dean; Anacleto D Gano; Kevin Knight; Joshua J Ofman; Ronnie Fass
Journal:  Clin Gastroenterol Hepatol       Date:  2004-08       Impact factor: 11.382

Review 9.  How to manage refractory GERD.

Authors:  Joel E Richter
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2007-12

Review 10.  Systematic review of endoscopic treatments for gastro-oesophageal reflux disease.

Authors:  D Chen; C Barber; P McLoughlin; P Thavaneswaran; G G Jamieson; G J Maddern
Journal:  Br J Surg       Date:  2009-02       Impact factor: 6.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.